There were 217 press releases posted in the last 24 hours and 150,285 in the last 365 days.

Seasonal Allergic Rhinitis Treatment Pipeline Review H2 2016

Global Seasonal Allergic Rhinitis Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued projects.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @ https://www.wiseguyreports.com/reports/643476-seasonal-allergic-rhinitis-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis
- The report reviews pipeline therapeutics for Seasonal Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seasonal Allergic Rhinitis therapeutics and enlists all their major and minor projects
- The report assesses Seasonal Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seasonal Allergic Rhinitis

Get Sample Report @ https://www.wiseguyreports.com/sample-request/643476-seasonal-allergic-rhinitis-pipeline-review-h2-2016

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ https://www.wiseguyreports.com/enquiry/643476-seasonal-allergic-rhinitis-pipeline-review-h2-2016

Table of Content
Seasonal Allergic Rhinitis Overview 6
Therapeutics Development 7
Pipeline Products for Seasonal Allergic Rhinitis - Overview 7
Seasonal Allergic Rhinitis - Therapeutics under Development by Companies 8
Seasonal Allergic Rhinitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Seasonal Allergic Rhinitis - Products under Development by Companies 11
Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development 12
Allergy Therapeutics Plc 12
Faes Farma, S.A. 13
Glenmark Pharmaceuticals Ltd. 14
Hisamitsu Pharmaceutical Co., Inc. 15
Merck & Co., Inc. 16
Pfizer Inc. 17
Shionogi & Co., Ltd. 18
VentiRx Pharmaceuticals, Inc. 19
Seasonal Allergic Rhinitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
asapiprant - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
bilastine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
desloratadine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
emedastine difumarate - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GSP-301 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PF-06444752 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
PF-06444753 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Pollinex Quattro Tree - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
VTX-1463 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Seasonal Allergic Rhinitis - Dormant Projects 43
Seasonal Allergic Rhinitis - Discontinued Products 45
Seasonal Allergic Rhinitis - Product Development Milestones 46
Featured News & Press Releases 46
May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis 46
Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN 46
Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use 47

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643476
Continued…

Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here